Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cubist Sets Sights On European Antibiotics Market With Zurich Move: A Conversation With Patrick Vink

Executive Summary

Cubist recently has seen its key antibiotic Cubicin become a blockbuster in the U.S. It is determined to take this success, backed by a flourishing pipeline, to answer Europe's call for products to fight antimicrobial resistance.

You may also be interested in...

Cubist Leadership Transitions To Perez With ‘Strong Hand To Play’

President and Chief Operating Officer Robert Perez will succeed Michael Bonney as CEO effective Jan. 1, taking over the top leadership spot at a time when the specialty pharma is in the midst of a transformation into a multi-asset company.

High-Value Antibiotics ‘Should Be Priced Accordingly,’ Cubist Exec Says

Incentives added under GAIN may not be “the end-all or be-all” but they are “a good start,” Cubist’s Steven Gilman says. Five years of additional exclusivity can mean a lot to smaller companies, and he thinks the clinical benefit of new drugs can support prices matching that value.

Antibiotic Policy Solutions An Ocean Apart Between U.S., EU

Governments are taking on different initiatives to solve the problem of developing products to address worries about drug-resistant bacteria. The EU is helping to fund trials, while the U.S. is offer extended exclusivity.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts